Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolates
LABT•Lakewood-Amedex reported positive lab data for Nu-3 against bacterial samples from infected diabetic foot ulcers; the topical Phase 2a trial’s topline results are expected in Q1 2027.
1. Lab data and trial
Lakewood-Amedex Biotherapeutics reported positive lab data for Nu-3 against recent bacterial samples from infected diabetic foot ulcers. The company said the findings support broad activity against resistant pathogens, without detailing performance metrics; Nu-3 is being tested in a topical Phase 2a trial, with topline results expected in Q1 2027.
